Vimarsana
Biggest News Aggregation in the World

Page 4 - World Dynamix News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from World Dynamix. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In World Dynamix Today - Breaking & Trending Today

BMS' Zeposia and AbbVie's Skyrizi Shake Up First-Line Prescribing Patterns in the US Ulcerative Colitis and Crohn's Disease Markets, Spherix Reports - Vimarsana News

BMS' Zeposia and AbbVie's Skyrizi Shake Up First-Line Prescribing Patterns in the US Ulcerative Colitis and Crohn's Disease Markets, Spherix Reports

/PRNewswire/ -- US gastroenterologists estimate that just under 60% of their ulcerative colitis (UC) and 55% of their Crohn's disease (CD) patients treated...

Off-Label Avastin (Genentech) Dominates First-Line Biologic Use in Diabetic Retinopathy Despite Eylea's (Regeneron) Best Efforts to Secure Share in the Space, According to Spherix Global Insights - Vimarsana News

Off-Label Avastin (Genentech) Dominates First-Line Biologic Use in Diabetic Retinopathy Despite Eylea's (Regeneron) Best Efforts to Secure Share in the Space, According to Spherix Global Insights

/PRNewswire/ -- Despite the availability of on-label products to treat diabetic retinopathy (DR), Genentech's off-label option, Avastin, is the predominant...

European Lupus Market Coverage Highlights Pipeline Perceptions and Country Differences in Patient Management, Spherix Reports - Vimarsana News

European Lupus Market Coverage Highlights Pipeline Perceptions and Country Differences in Patient Management, Spherix Reports

/PRNewswire/ -- Rheumatologists have long struggled to effectively treat patients with systemic lupus erythematosus (SLE) given the wide heterogeneity of the...

Despite Amplified Use of SGLT2 Inhibitors for Glomerular Diseases, EU and US Nephrologists Express a Continued Strong Desire for New Treatment Options for FSGS Patients, Spherix Reports - Vimarsana News

Despite Amplified Use of SGLT2 Inhibitors for Glomerular Diseases, EU and US Nephrologists Express a Continued Strong Desire for New Treatment Options for FSGS Patients, Spherix Reports

/PRNewswire/ -- Focal segmental glomerulosclerosis (FSGS) is one of the leading causes of nephrotic syndrome across the world and is considered the most common...

New IBD Mechanisms of Action Are Poised to Gain EU5 Patient Switches as Anti-TNF Therapy Efficacy Fades in Ulcerative Colitis and Crohn's Disease, According to Spherix Global Insights - Vimarsana News

New IBD Mechanisms of Action Are Poised to Gain EU5 Patient Switches as Anti-TNF Therapy Efficacy Fades in Ulcerative Colitis and Crohn's Disease, According to Spherix Global Insights

/PRNewswire/ -- According to the latest report published as part of Spherix's RealWorld Dynamix™: Biologic/Small Molecule Switching in IBD (EU) service, EU...